Clinical Trial Update: Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating furmonertinib at 160 mg versus 80 mg with chemotherapy in EGFR-mutated non-small cell lung cancer with brain metastases; status is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non-small Cell Lung Cancer (NSCLC), Brain Metastases | Phase 2 | Status: NOT_YET_RECRUITING